METHODS: Patients with an overt allergic reaction to LD (1/32 HE [≤100 mg]) or less, egg white (EW) protein within 6 months were included. In the VLD group, patients not achieving full-dose OFC (1/2 HE: 1600 mg EW protein) within 2 years were excluded. We retrospectively compared the rate of passing a full-dose OFC between patients who underwent a LD OFC before 2019 (LD group) and those who underwent a VLD OFC (1/100 HE: 32 mg EW protein) after 2019 (VLD group). The period for passing the full-dose OFC was evaluated using Kaplan-Meier survival analysis.
RESULTS: We enrolled 411 and 111 patients in the LD and VLD groups, respectively. The median age at OFC initiation was 2.2 [1.5-3.6] and 2.1 [1.4-3.2] years in the LD and VLD groups, respectively. EW- and ovomucoid-specific IgE levels were 38.3 (12.5-72.9) and 21.0 (8.3-46.2) kUA/L in the LD group and 49.8 [18.8-83.9] and 32.1 [15.6-67.8] kUA/L in the VLD group, respectively. Over 4 years, the LD and VLD groups passed the full-dose OFC at rates of 70 and 95%, respectively, with significant differences (log-rank test, P < 0.001).
CONCLUSIONS: VLD HE OFC may contribute to passing a full-dose OFC in patients with severe HE allergies.
方法:对LD(1/32HE[≤100mg])或以下有明显过敏反应的患者,包括6个月内的蛋清(EW)蛋白。在VLD组中,我们排除2年内未达到全剂量OFC(1/2HE:1600mgEW蛋白)的患者.我们回顾性比较了2019年之前接受LDOFC的患者(LD组)和2019年之后接受VLDOFC(1/100HE:32mgEW蛋白)的患者(VLD组)的全剂量OFC通过率。使用Kaplan-Meier生存分析评估通过全剂量OFC的时间。
结果:我们在LD和VLD组中招募了411和111名患者,分别。LD和VLD组开始OFC的中位年龄为2.2[1.5-3.6]和2.1[1.4-3.2]岁,分别。LD组的EW-和卵粘素特异性IgE水平分别为38.3(12.5-72.9)和21.0(8.3-46.2)kUA/L,VLD组的49.8[18.8-83.9]和32.1[15.6-67.8]kUA/L,分别。超过4年,LD和VLD组以70%和95%的比率通过了全剂量OFC,分别,具有显著差异(对数秩检验,P<0.001)。
结论:VLDHEOFC可能有助于严重HE过敏患者通过全剂量OFC。